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Abstract
The advent of targeted therapeutics in human cancer has begun to find novel druggable targets and, in this
context, the endothelin-1 receptor (ET-1R), namely ETA receptor (ETAR) and ETB receptor, among the GPCR family
represents a class of highly druggable molecules in cancer. ET-1R are aberrantly expressed in human malignancies,
potentially representing prognostic factors. Their activation by ligand stimulation initiate signaling cascades
activating different downstream effectors, allowing precise control over multiple signaling pathways. ET-1R
regulates cell proliferation, survival, motility, cytoskeletal changes, angiogenesis, metastasis as well as drug
resistance. The molecular events underlying these responses are the activation of transcriptional factors and
coactivators, and downstream genes, acting as key players in tumor growth and progression. ET-1R represent
crucial cancer targets that have been exploited for ET-1R therapeutics. Importantly, efforts to explore new
information of ETAR in cancer have uncovered that their functions are crucially regulated by multifunctional
scaffold protein β-arrestins (β-arrs) which orchestrate the multidimensionality of ETAR signaling into highly
regulated and distinct signaling complexes, a property that is highly advantageous for tumor signaling.
Moreover, the role of β-arr1 in ET-1 signaling in cancer highlights why the pleiotropic effects of ET-1 and its
dynamic signaling are more complex than previously recognized. In order to improve therapeutic strategies
that interfere with the widespread effects of ET-1R, it is important to consider antagonists able to turn the
receptors “off” selectively controlling β-arr1-dependent signaling, highlighting the possibility that targeting
ETAR/β-arr1 may display a large therapeutic window in cancer.
Keywords: Endothelin, Endothelin receptors, Cancer, β-arrestin, G-protein coupled receptors
Background
The endothelin (ET) family comprises three isoforms of
small peptides, ET-1, ET-2 and ET-3, products of different
genes [1]. ET-2 and ET-3 differ from ET-1 only in two and
six amino acid residues, but are separate gene products,
with tissue-specific expression. They are synthesized as
precursor proteins of about 200 amino acid residues in
size, pre-pro-ETs, and then cleaved by a neutral endopep-
tidase to form an inactive precursor of about 37–41 amino
acids, big ETs. Finally, a family of ET-converting enzymes
operates the conversion of big ET to the mature 21 amino
acids peptides [1]. The levels of prepro-ET-1 are modu-
lated predominantly at the level of transcription, through
the involvement of several transcription factors, including
activator protein 1, nuclear factor kappa B (NFkB), fork-
head box protein O1 (FOXO1), hypoxia-inducible factor
1α (HIF-1α), and GATA2, although both physical and
chemical stimuli contribute to alterations in levels of
preproET-1 mRNA in physiologic and pathophysiological
conditions [1, 2]. In last years, a host of epigenetic modifi-
cations have been discovered that allow for precise tuning
of DNA exposure and read-out in ET system regulation,
also in cancer. Indeed, in colon cancer, hypermethylation
of ET-2 and ET-3 genes results in the epigenetic inacti-
vation of ET-2 and ET-3 mRNA and corresponding
protein [2]. Recent data highlighted a role of microRNAs
(miRNA) to directly target the 3’UTR of ET-1 mRNA
for turnover and subsequently to regulate its expression
[3], and the list of miRNAs that may modulate ET-1 ex-
pression in different cancers, including hepatocarcinoma
and gastric cancer, is growing [4, 5].
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ETs activate two receptor subtypes that belong to the
G protein-coupled receptors (GPCR), known as ETA re-
ceptor (ETAR) and ETB receptor (ETBR), displaying 63 %
similarity [1, 2]. The two receptors can be differentiated
by agonists and antagonists binding affinity and in their
cellular distributions. The ETAR binds ET-1 with the
greatest affinity, whereas ET-1, ET-2, and ET-3 all have
equal affinity for the ETBR. In human tissues alterna-
tively spliced ETAR and ETBR transcripts have been
reported, although the biological significance is still
unclear. Epigenetic regulation is important also in the
regulation of ET-1R in cancer. Silencing of the ETBR
gene by DNA methylation was observed in different
tumors, allowing to the downregulation of the receptor
expression [6]. Recently, it has been shown that miR-30a
functionally binds the ETAR 3’UTR, thereby inhibiting
ETAR expression in ovarian cancer [7]. Moreover, post-
translational modifications, such phosphorylation, palmi-
toylation, and glycosylation, seem to be essential for the
functional activity of both receptors [1, 2]. Based on the
expression profiles of the ET-1R, there are cancers that
predominantly express ETAR, such as ovarian, breast,
colon, renal, gastric, pancreatic thyroid, and nasopharyn-
geal cancers; cancers expressing ETBR, such as melan-
oma, glioblastoma and astrocytoma, and those cancers
expressing both ETAR and ETBR, such as bladder, lung,
vulvar cancers and Kaposi’s sarcoma [2, 6]. ET-1R has
been known for many years to regulate rapid signaling
pathways through the involvement of G proteins, accord-
ing with its nature of GPCR. In this canonical intracellular
signaling, after agonist binding, ETAR couples to pertussin
toxin-insensitive Gq/11 and Gq12/13 proteins, whereas
ETBR couples to Gi/q and Gq/11 proteins [1, 2, 6]. Besides
G-proteins, GPCR also activates a parallel set of intracel-
lular pathways engaging with β-arrestin (β-arr) -1 or -2,
scaffolding proteins that directly bind GPCRs recognizing
the agonist-occupied receptor conformation [8, 9] (Fig. 1).
This review is divided into four parts. We first outline
how ET-1/ET-1R axis actually underlies many features
of cancers; in the second part, we review a large body of
works on the specific role of β-arrs in different tumors;
in the third part, we detailed the various β-arr-dependent
signalings upon ET-1R activation in cancer. Finally, in the
fourth part, we delineate the ET-1R cancer therapeutics
capable to hamper β-arr-mediated signaling.
Role of endothelin-1 signaling in cancer
Accumulating evidences demonstrated that activation of
autocrine or paracrine signalings by ET-1R in cancer are
complex regulatory mechanisms, and dysregulation of
the ET-1R signaling is crucial for the development and
progression of several human cancers [2, 10]. Indeed,
ET-1R activation, through a G-protein dependent or β-
arr-dependent mechanism, modulates different cancer-
associated signaling pathways, including MAPK, NF-kB,
β-catenin, PI3K/Akt and Rho GTPase, representing one
of the major mediators of cell survival and proliferation,
drug resistance, angiogenesis, osteogenesis, immune
modulation, invasion and metastasis. Moreover, the
complexity of ET-1R-mediated signaling is illustrated by
its integrative crosstalk with non-GPCR driven signaling
cascades, such as the epidermal growth factor receptor
(EGFR), vascular endothelial growth factor receptor
(VEGFR-2) or c-Src, creating further opportunities for
therapeutic intervention [2, 10] (Fig. 1).
ET-1 is now considered responsible for the proliferation
activity of different human cancer cells, acting alone or
in cooperation with other tumor-related growth factors,
favoring the activation of survival pathways [2, 6, 10].
ET-1-induced tumor promoting activities is also devoted
to control migration and invasion, as well as epithelial-to-
mesenchymal transition (EMT) and metastatic growth,
most likely as consequence of a precise control over
multiple signals, ranging from β-catenin signaling, EMT-
related factors, integrin signaling as well as gap junction
intercellular communication disruption [2, 10]. To invade
and colonize targeted tissues, an ET-1R-driven effect
involves also upregulation of expression, secretion and
activation of several matrix metalloproteinases (MMPs),
leading to enhanced pericellular protease activity [2, 10].
More recently, new studies on the interactions of ET-1R-
driven pro-invasive pathways have highlighted that the
mechanism by which cancer cells migrate through the
extracellular matrix (ECM) is related to formation of inva-
dopodia, specialized protrusions of the cell membrane of
invasive tumour cells, rich in MMPs, facilitating their
movement through the basement membrane and hence
promoting tumour intravasation and metastasis [11, 12].
Strictly related to cancer progression and challenge in
therapeutics, ET-1R is now recognized critically involved
also in drug resistance and in the adaptive changes, like
cancer stem cell (CSC) traits that, together with EMT, ex-
acerbate metastatic spread and drug resistance [10]. In
this context, in ovarian cancer ETAR overexpression
correlates with platinum resistance, EMT marker expres-
sion and phenotypic changes consistent with stemness
[13–16]. Similarly, high levels of ET-1 are expressed in
CSC of colon cancer, thus underling the complex action
exerted by ET-1R signaling in affording tumor cells inva-
sive and metastatic properties, EMT, CSC-like phenotype,
and drug resistance [2, 10].
Emerging data indicate also that ET-1R is capable of
re-educating tumor-host environment, composed of im-
mune cells, fibroblasts, and endothelial cells (EC), as well
as growth factors, proangiogenic mediators, cytokines,
chemokines, and other components of ECM, to form
one that is “permissive”, in which multiple interactions
between cancer cells and stroma determine not only
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tumor growth and metastasis but may also develop pro-
tective effects [2, 10]. The most studied and appreciated
mechanism of ET-1 signaling in tumor microenviron-
ment regards its involvement to direct angiogenesis and
lymphangiogenesis through ETBR expressed on blood
and lymphatic EC, and the critical interplay with hyp-
oxia, maintaining constant angiogenic and pro-tumoral
responses [2, 17–19]. Other studies demonstrated also
integration between ET-1 axis signaling and cancer-
associated fibroblasts or mesenchymal stromal cells in the
formation of a supportive tumour stroma [2, 17, 18, 20].
An increased understanding of the mechanisms by which
cancer cells escape the immune system recognizes now
ET-1 axis as capable to mediate complex interactions
between immune cells and malignant cells, acting on
different subsets of immune effectors and regulatory
cells, such as dendritic cells and tumor-associated mac-
rophages [2, 10]. A critical interplay between ET-1 axis
Fig. 1 Signaling pathways activated by ET-1 in cancer. The endothelin- 1 receptor (ET-1R) is a G-protein coupled receptor, that upon agonist
binding, results in the activation of G-protein-dependent primary effectors including phospholipase Cβ (PLCβ), which cleaves phosphatidylinositol- 4,5-
bisphosphate (PtdIns(4,5)P2) into diacylglycerol (DAG) and inositol triphosphate (IP3), leading to calcium mobilization and protein kinase C (PKC)
activation, and downstream activation of MAPK family members, including ERK1/2. At the same time, ET-1R activation stimulates Ras/Raf/MEK
activation, converging on ERK1/2 signaling. Moreover, ET-1R receptor stimulation activates phospholipase A (PLA) and downstream arachidonic acid
(AA) and cyclooxygenase-1 (COX-1) and COX-2, leading to prostaglandin E2 (PGE2) release, as well as phosphatidylinositol-3-kinase (PI3K), leading to
the activation of AKT, integrin-linked kinase (ILK) and glycogen synthase kinase (GSK)-3β, which stabilizes β-catenin. Notably, ET-1R can also signal via
β-arrestin1 (β-arr1) to activate ERK1/2 and PI3K/AKT/β-catenin signaling. β-arr1 also controls the crosstalk between ET-1R and epidermal growth factor
receptor (EGFR) through the recruitment and activation of c-Src, resulting in downstream pathway activation. Through β-arr1, ET-1 activates also
nuclear factor-kB (NF-kB) signaling via inhibition of NF-kB inhibitor (IkB), resulting in the dissociation and subsequent nuclear localization of active
NF-kB. On the other hand, β-arr1 mediates ET-1-induced hypoxia-inducible factor 1α (HIF-1α) activity promoting vascular endothelial growth factor
(VEGF) release. Moreover, ET-1R activates PDZ-RhoGEF leading to Rho-A and -C GTPase activation, initiating Rho-dependent signaling events through
RHO-associated coiled-coil containing protein kinase 1 (ROCK1), LIMK activation, causing cofilin inhibition and cytoskeletal remodelling.
The cooperation of these intracellular signaling pathways promote cell growth, chemoresistance, angiogenesis, cytoskeleton remodelling, invadopodia
formation, and metastasis
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and T cell–infiltrated phenotype that might prevent T
cell homing to tumor endothelium and hinders tumor
immunotherapy has been shown in ovarian cancer and
in gliomas [13, 21, 22], indicating that ET-1R has the
potential to significantly change the ongoing immune
response in the tumour microenvironment. In the bi-
directional cross-talk between cancer cells and stromal
cells, ET-1 signaling is implicated in a series of sequential
and interrelated steps, also involved in chemoprotective
signals [2, 23–25]. These findings extent previous findings
regarding the role of ET-1 signaling in promoting metas-
tasis [26–29], as recently reviewed [2, 10].
The role of ET-1R in the complexity of the tumor
microenvironment interactions, and the importance of
cell-cell interactions, led to evaluate its expression as
potential biomarker in cancer diagnosis and treatment.
Levels of ET-1 are higher in patients with bladder can-
cers, which are prone to metastasize, correlating with
reduced patient survival, thus indicating ET-1 as a bio-
marker for lung metastasis [30]. Analysis of human
ovarian cancer tissues demonstrated that ETAR overex-
pression is associated with worse survival, in particular
in advanced stages and in the subset of platinum resis-
tant cases [15]. However, many other studies need for
optimizing the use of ET-1R to identify patients who
are likely to respond to a given therapy, as well as for
measuring patient response to therapy.
Role of β-arrestin in cancer
Emerging data have revealed that β-arr recruitment
represents a major non-G protein-dependent signaling
pathway of GPCR, like ET-1R, in cancer. This function
is largely related to the ability of β-arr to act as multi-
functional adaptor capable to finely modulate multiple
signaling pathways involved in tumor growth and metas-
tasis, driven mainly by GPCRs (Table 1), but also by
other non-GPCR pathways, such as transforming growth
factor (TGF)-β, Hedgehog, Wingless, and Notch. Indeed,
β-arr may directly interact with a plethora of proteins
with various functions and localization, including nu-
clear proteins and cytoskeletal components [8]. One the
best characterized signaling pathways mediated by β-arr
is linked to non-receptor tyrosine kinase c-Src. Indeed,
in different human cancer, such as prostate, colorectal,
breast or gastric cancer, a complex and functional inter-
action between β-arr and c-Src driven by activation of
GPCR, like prostanoid receptor 4, chemokine receptor-7
or GPR39, mediates the cross-talk with other several sig-
naling, such as EGFR or Wnt signaling, representing
additional mechanisms by which GPCR can sustain
long-term biological responses [31–34]. The knowledge
of the mechanisms activated by β-arr increased our un-
derstanding of its role to form and maintain signals, as
an oncogenic hub, to direct cytoskeleton reorganization
and to facilitate cancer cell migration induced by GPCR.
β-arr function as signaling scaffolds to sequester regula-
tors of actin assembly at the leading edge and to inte-
grate multiple signaling molecules, fine tuning their
signaling capacity in cell migration [35]. This regulation
can occur either by scaffolding signaling proteins, such
as Arp2/3 complex and WASP family of proteins or
Rap1, RhoA and Ral GTPases, or by directly binding
Table 1 Roles of β-arrestins in human cancers
β-arr isoform Tumor type Role in cancer References
β-arr1/β-arr2 Ovarian cancer Chemoresistance, angiogenesis, migration, invasion, metastasis [11, 15, 28, 29, 56,
58–61]
β-arr1 Lung cancer Cell growth, migration, metastasis, stemness, angiogenesis Poor prognosis [40–42, 54, 55, 62–66]
β-arr1/β-arr2 Prostate cancer Cell viability and proliferation, chemoresistance, migration, metabolic alteration
Regulator of androgen receptor expression
[32, 46, 48, 53, 66–68]
β-arr1 Acute lymphoblastic leukemia. Cell growth, stemness
Poor prognosis
[45, 69]
β-arr1/β-arr2 Chronic myeloid leukaemia Cell growth, stemness
Poor prognosis
[44, 70, 71]
β-arr1/β-arr2 Colorectal cancer Cell growth, apoptosis, migration, invasion and metastasis [33, 72–75]
β-arr1 Gastric cancer Cell proliferation
Poor prognosis
[34, 76]
β-arr1 Osteosarcoma Proliferation and invasion [77]
β-arr1/β-arr2 Breast cancer Cell proliferation, migration and invasion and metastsis
Multidrug resistance
[31, 36, 47, 50, 57,
78–86]
β-arr1 Neuroblastoma Metastasis [87]
β-arr1 Ewing's sarcoma Drug resistance [88]
β-arr1 Melanoma Angiogenesis [89]
β-arr2 Pancreatic cancer Cell proliferation [90]
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cytoskeleton proteins, such as proteins of cytoskeletal
filaments, cytoskeletal accessory proteins, and motor
proteins [35]. In agreement with these data, a global
phosphorylation analysis of β-arr-mediated signaling
identified a cytoskeleton reorganization network whereby
β-arrs regulate phosphorylation of several key proteins
[36, 37], during cancer cell migration and invasion.
Besides cytoplasmic functions, so far unexpected nu-
clear activities of β-arr are recently reported [38]. Thus,
β-arr1 appears to regulate directly transcription causing
nuclear interaction of β-arr1 with selected gene promoters
and the recruitment of the histone acetyltransferase p300,
thus enhancing local histone acetylation and gene tran-
scription [39]. Following studies identified nuclear β-arr1
as a critical mediator of nicotine-induced human non-
small cell lung cancer progression (NSCLC). Indeed, nu-
clear β-arr1/E2F1 complex on promoters of specific target
genes drives proliferation, survival and EMT, as well as
stemness [40–42]. Recently, it has been shown that β-arr1
contributes also to endothelial dysfunction promoted by
nicotine, by promoting its recruitment to the E-selectin
promoter as well as E-selectin expression, thus facilitating
adhesion of monocytes to EC and endothelial damage,
revealing a novel role for nuclear β-arr1 in the growth and
metastasis of NSCLC [43]. Other studies depicted nuclear
roles of β-arr1 in regulating the dynamic of gene ex-
pression in cancer cells by controlling the recruitment of
epigenetic regulators, acting in histone modifications or
DNA methylation [44–46]. More recently, it has been
shown that nuclear β-arr1 play a critical role in facilitating
adaptation of cancer cells to growth in conditions of meta-
bolic alterations, called “pseudohypoxia”. Although it was
already demonstrated that nuclear β-arr1 interacts with
the primary factor mediating the response to low oxygen
tension HIF-1α in breast cancer cells, a first genome wide-
map of β-arr1 transcriptome in prostate cancer cells re-
ported binding sites for β-arr1, p300 and HIF-1α on the
regulatory regions of HIF-1α target gene promoter under
hypoxic or pseudohypoxic conditions [47, 48]. This
genomic landscape of β-arr1, revealing a partial overlap
between β-arr1 and p300 binding sites, and the presence
of non-overlapping sites, indicates that β-arr1 may also
modulate transcription independently of p300, and also
that exploring more in depth the nuclear function of β-
arr1 might add one more layer of specialization of β-arr1
activities. The list of β-arr nuclear functions is growing
very fast, and includes also new specific activities [49, 50].
Some of these specializations may also include an indirect
way to control transcription, as demonstrated for a direct
anti-apoptotic action of β-arr1 activated via β(2)-adrenore-
ceptors at the core of cell death machinery, in which
nuclear β-arr1 facilitating activation of MDM2 and deg-
radation of p53 promotes DNA damage accumulation
[51]. On the other hand, the localization of several β-arr
binding partners, such as JNK3, NF-kB and MDM2, are
also regulated by ability of β-arr2 to retain them in the
cytosol, and to change interactions with ubiquitinating
and deubiquitinating enzymes, thus controlling crucial
factors, such as p53, Wnt/β-catenin and FOXO1 [52, 53].
Using data from the Cancer Genome Atlas (TCGA)
portal for β-arr1 expression across various tumor data-
sets, it has been shown that β-arr1 is amplified in vari-
ous tumors, especially in high-grade ovarian cancer [10].
Interestingly, in patients with lung adenocarcinoma, the
β-arr1 overexpression is an independent prognostic fac-
tor for tumor progression and unfavorable overall sur-
vival, suggesting a role of β-arr1 as promising biomarker
to identify patients with poor prognosis [54]. In agree-
ment with these findings, it has been demonstrated that
in lung adenocarcinoma patients, co-expression of nuclear
β-arr1 and p65 represents a novel predictor for worse
prognosis [55]. Also, the higher expression of β-arr1 is
positively correlated with clinical phases of chronic
myeloid leukemia patients [44]. Given that the multidi-
mensionality of β-arr confer highly advantageous signals
to cancer cells, investigating whether β-arr can represent
a prognostic factor will certainly emerge as the next
challenge in the future cancer research studies.
Multifunctional role of β-arrestin in ET-1 signaling in cancer
It has been shown that different GPCR signal through
parallel pathways or support ligand bias to stimulate or
promote different cellular responses, based on the ability
of ligands to selectively activate G-protein- or β-arr-
dependent signaling pathways. Considerable amount of
data have been accumulated showing that β-arr1 plays a
major role in tumor-promoting effects of ET-1R signaling
in cancer [2, 10]. These studies highlighted the formation
of new ET-1R-driven β-arr-mediated multiprotein signal-
ing complexes, known as a “signalosomes,” in which β-arr
acts as cytosolic or nuclear scaffold, adaptor, and signal
transducer, orchestrating a variety of fine-tuned intracellu-
lar signaling pathways than culminate in sequential steps
of tumor progression. Recently, new roles for β-arr1 have
emerged in ET-1 signaling, sequestering and bringing the
right players for actin assembly activities and upstream
regulators at the leading edge to drive local invasion and
metastasis [11, 56]. Thus, ETAR/β-arr1 signaling repre-
sents a novel driver of cytoskeletal organization and Rho
GTPase activity supporting cell motility. In ovarian cancer
cells, ET-1 through β-arr1 activates RhoA GTPase and,
downstream, Rho-associated coiled coil-forming kinase 1
(ROCK1) kinase activity, leading to enhanced cell mi-
gration and protrusion formation. Most importantly, it
has been revealed that β-arr1 acts as signal-integrating
module of Rho GTPase activity for specific formation
and maturation of invadopodia, small invasive protrusions
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of localized protease activity, which are formed in
response to signaling events leading to dynamic branched
actin assembly at membrane sites and are cellular hot-
spots for secretion of proteinases degrading ECM.
This is accomplished by the direct interaction of β-arr1
with a Rho guanine nucleotide exchange factor (GEF),
PDZ-RhoGEF, which activates Rho GTPase proteins by
catalyzing the exchange of GDP for GTP. Interestingly,
β-arr1/PDZ-RhoGEF interaction mediates ETAR-driven
ROCK-cofilin pathway through the control of RhoC ac-
tivity. This novel interaction is functional to invadopodia
formation and activation of key invadopodia proteins,
cortactin, cofilin and membrane type I (MT1)-MMP.
Collectively, these data unveiled a noncanonical activa-
tion of the RhoC/ROCK pathway through the β-arr1/
PDZ-RhoGEF complex, establishing ET-1R/β-arr1 axis
as a novel regulator of invadopodia protrusions during
tumor invasion [11]. These results are in line with previ-
ous findings demonstrating the role of β-arr in control-
ling the cofilin pathway localizing actin to the leading
edge of cells to promote invasive protrusions during
tumor cell migration [12, 35, 57].
Different studies demonstrated that the recruitment
of β-arr to ETAR represents a checkpoint controlling
pathways converging on β-catenin signaling to promote
ovarian cancer invasion and metastasis. Indeed, after
binding of ET-1 to ETAR, β-arr1 and β -arr2 were re-
cruited to the receptor, to form at least two trimeric
signaling complexes or “signalplexes”: one through the
interaction with c-Src leading to EGFR transactivation
and, downstream, β-catenin tyrosine phosphorylation,
and the another through the physical association with
axin, contributing to release and inactivation of glyco-
gen synthase kinase-3β and β-catenin stabilization, both
concurring to activate β-catenin signaling pathways,
and to activate transcription of genes involved in EMT,
invasion and metastasis [28]. Most important, in xenograft
models of intraperitoneal ovarian cancer metastasis, cells
expressing a mutant β-arr ineffective to bind c-Src show
reduced metastatic ability, and reduced expression of ac-
tive β-catenin is observed in the metastatic nodules [28].
Of clinical relevance, ETAR is expressed in 85 % of ovarian
cancer and is preferentially co-expression with β-arr in the
advanced tumors, further revealing the pathophysiological
role of β-arr1 and ET-1R in tumor progression [28]. To
underscore the complexity of the mechanisms available to
ETAR to interlink β-catenin pathways, it has been ex-
plored whether β-arr1 may also provide a link between
ETAR and β-catenin transcription as nuclear scaffolding
mediating epigenetic modification [29]. The mechanism
underlying ET-1-driven final transcriptional output of β-
catenin includes ETAR-dependent β-arr1 nuclear trans-
location, direct binding to β-catenin and their nuclear
accumulation (Fig. 2). β-arr1/β-catenin interactions, by
favouring the dissociation of histone deacetylase 1 and
the recruitment of p300 on β-catenin target gene pro-
moters, such as ET-1, AXIN2, MMP2 and cyclin D1,
result in enhanced gene transcription, required for cell
migration, invasion and metastasis. Thus, silencing of
β-arr1 or nuclear mutant β-arr1 expression inhibits
ovarian cancer metastasis [29]. The findings of in vivo
direct β-arr1/β-catenin association at specific β-catenin
target gene promoters derived from analysis of human
ovarian cancer tissues, correlating with tumor grade,
unravel new components in the role of β-arr1 as critical
nuclear mediator in cancer [29]. Additional studies
identified β-arr1 as a co-pilot of ETAR to organize com-
plex signaling networks also controlling EMT phenotype,
stemness features and drug resistance, expanding previ-
ously knowledge about the chemoresistance-associated
functions of ETAR. Indeed, ETAR/β-arr1-driven epigenetic
modifications and β-catenin transcription sustain che-
moresistance onset by enhancing transcription of genes,
such as ET-1, linked to chemoresistance [15]. The general
idea is that the spectrum of pathways and interactions
through which β-arr1 might regulate cancer invasion,
metastasis, and chemoresistance, is more then until now
demonstrated. Indeed, in melanoma cells, the cytosolic
scaffold function of β-arr1 is also necessary to activate
crosstalk with VEGFR-2, promoting melanoma cell plas-
ticity, motility, and neovascularization [10].
More recently, a novel mechanism of β-arr1 nuclear
function in ET-1R signaling involving HIF-1α activity
has been described (Fig. 2). In ovarian cancer cells, acti-
vation of ETAR, by mimicking hypoxia, induces the
nuclear β-arr1/HIF-1α interaction and the recruitment
of p300 to hypoxia response elements of gene targets,
resulting in enhanced histone acetylation, transcription
and thus release of HIF-1α targets, such as ET-1 and
VEGF, required for tumor cell invasion and pro-
angiogenic effects in ECs [58]. These results highlight
the presence of a self-amplifying HIF-1α-mediated tran-
scription of ET-1 sustaining a regulatory circuit in-
volved in invasive and angiogenic behaviours. These
findings broaden previous data in prostate and breast
cancer [47, 48]. The intriguing role of nuclear β-arr1
was further amplified by other findings revealing a pre-
viously unrecognized pathway that depends on β-arr1
to sustain NF-kB signaling in response to ETAR activa-
tion [59]. Collectively, these multiple lines of evidence
underscore more appealing aspects of β-arr1 as transducer
of ET-1 signaling during cancer progression, including
cytoskeletal organization.
All these findings suggest that further investigations
are required to elucidate the role and regulation of these
metastatic promoting functions driven ET-1R signaling,
to determine the degree of which is dictated by the G-
protein-dependent and β-arr dependent signaling as
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well as the involvement of β-arr isoforms, that will aid
in the identification of new targets for the design of novel
therapeutics against cancer. In this regard, in ovarian
cancer model it has been clearly depicted the functional
selectively of β-arr-dependent signaling driven by ET-
1R [10, 60], that promotes biological responses differing
quantitatively and qualitatively in promoting tumor
progression. Thus, β-arr1 responds to ET-1R activation
reflecting changes in the dynamic of actin cytoskeleton,
which appears to be crucial to integrate multiple sig-
nals, setting β-arr functions as an absolute requirement
for cancer signaling.
Clinical potential of ET-1R therapeutics controlling
β-arrestin signaling
ET-1R is now considered one of the most attractive
therapeutic targets in cancer, representing one of the
best-characterized systems with respect to functional
consequences of GPCR–β-arr interactions. Different
findings reveal that ETAR/β-arr interaction is fully en-
gaged in transmitting signals from the membrane to nu-
cleus, promoting early and late events leading to tumor
progression. These data illustrate also the utility in the
translation of the concept of seeking antagonists with
functional selectivity respect to G-protein-independent
Fig. 2 Nuclear function of β-arrestin1 in ET-1 signaling. Binding of ET-1 to ETAR leads to the recruitment of β-arr1 to the activated receptor, which
mediates the phosphatidylinositol 3-kinase (PI3-K)/integrin linked kinase (ILK)/Akt signaling route, which causes the phosphorylation and inactivation
of glycogen synthetase kinase 3β (GSK3-β) and accumulation of a non-Ser/Thr phosphorylated, active β-catenin. In parallel, ETAR/β-arr1 complex
binds axin, thereby promoting the release of GSK-3β from the β-transducin repeat containing protein (β-TrCP) and adenomatous polyposis coli
(APC)-mediated degradation machinery, and its inactivation. In turn, β-arr1 shuttles with β-catenin to the nucleus and by interacting with p300
histone acetyltransferase enhances β-catenin/T-cell-specific transcription factor-4 (TCF4) activation, thus promoting the transcription of genes,
such as ET-1, matrix metalloproteinase 2 (MMP-2), cyclin D1 and Axin 2, leading to enhanced cell motility and aggressiveness. Moreover, in
ET-1-dependent manner, β-arr1 shuttles into the nucleus, where it interacts with HIF-1α to form a transcriptional complex with p300 required for
histone acetylation and for the transcription of HIF-1α target genes, such as ET-1 and VEGF, a mechanism that can be amplified by hypoxia. Both
these signals lead to the amplification of the ET-1 autocrine loop
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and β-arr-dependent ET-1 signaling to block cellular
responses associated with tumor progression [10]. Con-
sidering the effects of β-arr as both cytoplasmic and
nuclear messengers in tumor invasion and metastasis as
well as in chemoresistance, the translation from basic
biology to clinical drug development might consider that
disruption of the ETAR/β-arr interaction can impair
EMT, invasion, metastasis and chemoresistance, sugges-
ting a possible avenue for therapeutic intervention. A
plethora of studies in different human cancer highlighted
the efficacy of targeting ETAR in vitro and in preclinical
models, in which ETAR blockade with different ETAR-
selective antagonists (atrasentan and zibotentan) results
in antitumour activity, by concomitant growth inhibition
and apoptosis induction, an effect that can be potenti-
ated from combined treatment of chemotherapeutics or
targeted therapy [2, 10]. The efficacy of this target therapy
is extended to control also drug-resistance and metastasis,
as shown in different tumor models [2, 10]. However, the
failure of clinical trials using selective antagonists and the
screening of antagonists tested for their ability to alter ET-
1-driven cancer cell growth and progression, uncovered
the dual ETAR/ETBR antagonist as a promising drug for
treatment of ET-1R-driven tumors. Macitentan is a non-
selective and dual ETAR/ETBR antagonist, approved for
the treatment of pulmonary hypertension [10]. Preclinical
data in different tumor models showed drug efficacy in
controlling tumor growth and metastasis, in monotherapy
or in combination with others drugs, such as chemothera-
peutic drugs, predicting clinical success [2, 10]. According
with a recurring theme in the utilization of molecularly
targeting therapeutics that should target both tumor cells
and microenvironment where tumor cells thrive, maciten-
tan simultaneously targets cancer cells, which typically
express ETAR, and stromal elements through ETBR,
enhancing antitumour immune and anti-angiogenic
mechanisms. Moreover, considering the decisive role of
ET-1 signaling in the physical interactions of cancer cells
and tumor-associated stromal cells, to sustain cancer
metastasis as well as to act as chemoprotective mediator,
this kind of drug represent a promising therapeutic op-
portunity [15, 24–27]. Mounting evidence suggests that
drugs, like macitentan, serve as effective tools for cancer
therapy also for the ability to selectively targeting specific
β-arr-dependent downstream signaling [10]. In ovarian
cancer, where it has been dissected the role of β-arr in
ET-1 signaling, in vivo, silencing of β-arr1 or macitentan
treatment, impairing the signaling pathways involved in
cell survival, EMT, and invasion, reduces tumor growth,
vascularization, intravasation, and metastatic progres-
sion, and potentiates the cytotoxic effects of cisplatinum
[15, 16]. Continuing efforts to fully understand the bio-
logical functions and associated mechanisms of ET-1R will
likely facilitate the development of new targets and
innovative pharmacological strategies for treating cancer
patients. Further investigations will hopefully drive pre-
clinical validated antagonists into clinical studies where
their true therapeutic efficacies against cancer vulner-
ability can be evaluated.
Conclusions
β-arr is a well-known primary effector of GPCR pathway,
crucial in tumor growth and progression. Increasing evi-
dences have provided insights into the regulation of this
protein and its mechanism of action. The findings
highlighted in this review offer a broad overview of the
biological activity elicited by ET-1R/β-arr in tumorigenesis
and metastasis progression. The above information indi-
cates that ET-1/ET-1R axis activates through β-arr1 many
signals on epigenetic inputs that sustain ET-1R activities
in cancer and tumor microenvironment. Cancer cells may
use different cytoplasmic and nuclear roles of β-arr1 in a
manner that may change between different tumors and
even into tumoral lesions. Thus an important aspect that
deserves attention is the mechanism by which nuclear
β-arr1 selects transcriptional partners, revealing new
players by which ET-1R/β-arr orchestrate cancer cell be-
haviour and outcomes. A better understanding of these
events may suggest therapeutic antitumoral strategies, for
example focusing on the ET-1R antagonist currently used
in clinical practice, allowing precise control over signaling
pathways. Clearly, being able to block ET-1R and turn-out
the β-arr functions would represent a new era for ET-1-
therapeutics to be exploited for cancer treatment.
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